NCT01759875 - Effects of Gastric pH on the Pharmacokinetics of Atazanavir | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 31, 2013

Primary Completion Date

January 31, 2014

Study Completion Date

January 31, 2014

Conditions

Healthy

Interventions

DRUG

Ritonavir-boosted Atazanavir

Ritonavir (100mg) PO x1 and Atazanavir (300mg) PO x1

DRUG

Ritonavir-boosted Atazanavir plus Rabeprazole

Rabeprazole (20mg) PO twice daily (Days 1-3); Ritonavir (100mg) PO x1 and Atazanavir (300mg) PO x1 (Day 4)

DRUG

Ritonavir-boosted Atazanavir plus Rabeprazole AND Betaine Hydrochloride

Rabeprazole (20mg) PO twice daily (Days 1-3); Betaine Hydrochloride (1500mg) PO x1 AND Ritonavir (100mg) PO x1 and Atazanavir (300mg) PO x1 on Day 4

Trial Locations (1)

Clinical Research Center, UCSF, San Francisco

All Listed Sponsors

lead

University of California, San Francisco

OTHER